By Lisa Kerner
Charlotte, N.C., Nov. 8 - Solstice Neurosciences, Inc. said it completed an $85 million combined series B equity funding and debt financing round.
Funds will be used for growth initiatives and product development, including Myobloc (Botulinum Toxin Type B) Injectable Solution.
Highland Capital Management, LP led the series B financing, joined by existing series A investors Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners and Oxford Bioscience Partners.
Aquilo Partners, Inc. was the placement agent for the equity funding.
Brett Pope and Nathan Hukill of Highland Capital Management will join Solstice's board of directors.
Solstice is a biopharmaceutical company based in Malvern, Pa.
| Issuer: | Solstice Neurosciences, Inc.
|
| Issue: | Series B equity funding and debt financing
|
| Amount: | $85 million
|
| Investors: | Highland Capital Management, LP (lead), Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners, Oxford Bioscience Partners.
|
| Announcement date: | Nov. 8
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
